Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$843.00M+22.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Que Thanh Dallara
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Employees
- 8,000
- Beta
- -3.71
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.28
Financials
MMED has only 7 quarterly periods on file — the charts below show the full history available.
Revenue
$843.00M+22.7%Net Income
$0.00EBITDA
$79.00M+33.9%Free Cash Flow
$-90.00MEPS (diluted)
$0.00Shares Outstanding (diluted)
281.00M+0.1%Operating Expenses
$427.00MCash & Debt
$207.00MReturn of Capital
$0.00Revenue by Segment (annual)
$1.55BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.10B | $-331.00M | $-1.29 |
| 2024 | $2.71B | $-250.00M | $-0.89 |
| 2023 | $2.47B | $-112.00M | $-0.40 |
| 2022 | $2.25B | $-96.00M | $-0.34 |
Valuation
MMEDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (21)
- News (RSS)seekingalpha·4d ago·Neutral
MiniMed: The Split-Off Hangover Is Hiding A Full-Stack Product Cycle
View source ↗ - Newsbenzinga.com·6d ago·Negative
FDA Clears MiniMed Fit Tubeless Insulin Pump with Seven-Day Wear MiniMed (NASDAQ:MMED) on Monday secured U.S. Food and Drug Administration clearance for MiniMed Fit, marking the company's debut in the tubeless insulin pump market with a device offering up to seven days of wear and a 300-unit insulin capacity.
View source ↗ - Newsprnewswire.com·6d ago·Negative
…es for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation NORTHRIDGE, Calif., Nov. 16, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit™, the company's first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
MiniMed to Participate in Upcoming Investor Conferences NORTHRIDGE, Calif., Nov. 5, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Chad Spooner, EVP, Chief Financial Officer, will discuss and answer questions on the company at the following investor conferences: 9th Annual Evercore Healthcare Conference Tuesday, December 1, 2026, at 10:50 a.m.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
MiniMed Appoints Dr. David Segal as Chief Medical Officer NORTHRIDGE, Calif., Nov. 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the appointment of David Segal, M.D.
View source ↗ - Newsprnewswire.com·38d ago·Neutral
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused on making every day a better day for people with diabetes. NORTHRIDGE, Calif.
View source ↗ - News (RSS)investing·46d ago·Neutral
Medtronic sets final exchange ratio for MiniMed split-off
View source ↗ - Newsprnewswire.com·48d ago·Neutral
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes Six-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders. NORTHRIDGE, Calif.
View source ↗ - News (RSS)yahoo·61d ago·Neutral
MiniMed (MMED): Nine Analysts Raised Targets, But Cash Flow Still Has a Catch
View source ↗ - News (RSS)seekingalpha·69d ago·Neutral
Medtronic launches exchange offer to complete separation of MiniMed
View source ↗ - Newsfool.com·79d ago·Neutral
Why MiniMed Stock Was Soaring This Week A new product introduction helped lift the top line. It seems there's more where that came from, with new product introductions scheduled over the coming months.
View source ↗ - Newsseekingalpha.com·80d ago·Positive
MiniMed Group: Recurring Revenues And Fresh Product Cycle MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.
View source ↗ - Newsbenzinga.com·81d ago·Neutral
These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results MiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.
View source ↗ - News (RSS)yahoo·81d ago·Negative
MiniMed (MMED) Soars on Revenue Growth, Price Target Hike; Hedge Fund Conviction Weakens
View source ↗ - News (RSS)yahoo·82d ago·Positive
Medtronic Flirts With A Breakout As Its Spinoff, MiniMed, Hits A Record
View source ↗ - Newsseekingalpha.com·82d ago·Positive
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·82d ago·Neutral
MiniMed Group Q1 Earnings Call Highlights MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
… for next-gen extended wear MiniMed sensor Raises fiscal year 2027 organic revenue growth guidance NORTHRIDGE, Calif., Sept. 1, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended July 31, 2026.
View source ↗ - Newsbenzinga.com·86d ago·Neutral
Top Wall Street Forecasters Revamp MiniMed Group Expectations Ahead Of Q1 Earnings MiniMed Group, Inc. (NASDAQ:MMED) will release its first quarter earnings report before the opening bell on Tuesday, Sept. 1.
View source ↗ - Newsprnewswire.com·89d ago·Neutral
MiniMed to Participate in Upcoming Investor Conferences NORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.
View source ↗ - Newsprnewswire.com·97d ago·Neutral
MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor MiniMed Flex™ with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif., Aug. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced that the MiniMed Flex™ system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott.
View source ↗
Earnings
Wed, Dec 30(in 5 weeks)
Consensus estimate $0.12 per share
Typical surprise -194.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 1$0.12 vs $0.12miss
- Wed, Jun 3$-0.68 vs $-0.15miss
- Fri, Apr 17$-0.16 vs $0.17miss
Estimates and results for MMED via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MMED officers and directors.
No open-market trades in the recent filings. All 99 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MMED.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
